In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that ...

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...

As cost-of-living soars, wars rage and stock markets fluctuate, we could all use a respite. The natural world has been proven ...